CAR T Cells Impact the Treatment Landscape Across Hematologic Malignancies
Mohamad Mohty, MD, PhD, discusses the promise of CAR T-cell therapy in hematologic malignancies. He says CAR T cells were the superstar of the 2018 ASH Annual Meeting.
Mohamad Mohty, MD, PhD, a professor of hematology at Saint-Antoine Hospital and University Pierre & Marie Curie, discusses the promise of CAR T-cell therapy in hematologic malignancies. He says CAR T cells were the superstar of the 2018 ASH Annual Meeting.
Efficacy and safety data have been seen in a number of areas, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma (NHL), and multiple myeloma. Mohty says the results are becoming more consolidated with very recent follow-up and promising survival curves.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
